Eli Lilly’s (LLY) new weight loss pill is still in clinical trials and has not yet been approved by regulators. But that hasn ...

Pharmaceutical company Eli Lilly (LLY) has been raking it in lately thanks to its two flagship products: Mounjaro and Zepbound. These two have ...

Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by ...

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...

Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

Klug, M.B.A., Appointed Chief Financial Officer and Chief Business Officer; Sophie Jeannin, M.D., Appointed Chief Medical ...

Healthcare costs and spending have been rising in the US. The Centers for Medicare & Medicaid Services reported that ...

Foreign investments in Flanders created 5,000 new jobs in 2024, with the United States accounting for 21.6% of total projects, including a strong presence in the pharmaceutical and biotech sectors.

As the demand for GLP-1 weight loss medications such as Ozempic, Wegovy, and Zepbound continues to skyrocket, new survey results from 9amHealth reveal that access to these medications has become a ...

Brisbane-based AdvanCell raised $178 million in one of the biggest funding rounds of 2025 so far. It's good news for an ...